- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Ann Partridge, MD, MPH
Professor of Medicine, Harvard Medical School
Director of the Adult Survivorship Program
Dana-Farber/Brigham and Women’s Cancer Center
Dana-Farber Cancer Institute
- Seeking to understand the complex medical and emotional problems facing young women with breast cancer.
- An intervention study is planned to provide resources and education, and track patient outcomes in newly diagnosed young women with breast cancer.
- This research will lead not only to new insights to inform future care and research of breast cancer in young women but will directly enhance the care of young breast cancer patients.
While breast cancer in women under 40 years old is rare, it is the most common cancer in young women. Women diagnosed with breast cancer at an early age face unique challenges, from treatment-induced sexual dysfunction and concerns about future pregnancies, to psychosocial issues and economic stability. Dr. Partridge is conducting studies to better understand these challenges to inform the care and treatment of young breast cancer patients.
Full Research Summary
Breast cancer is the leading cause of cancer-related deaths in women aged 40 years and younger in the United States. Dr. Partridge and her team will build on prior research to improve understanding of the complex medical and emotional problems facing young women with breast cancer, with a new focus on intervention and outreach.
The team will design and launch two parallel studies:1) the Young Women’s Breast Cancer Study 2 (YWS2), which will enroll newly diagnosed young women in their clinical program and 2) the Young Women’s Breast Cancer Study 2-Internet (YWS2i), which will engage a broader population of young breast cancer patients through a web-based platform.
In both studies, the research team will collect medical information and biological specimens and conduct participant surveys to gain insight on the impact of a breast cancer diagnosis and treatment for young women.
In the past year, Dr. Partridge’s clinical team has enrolled 1,302 young breast cancer patients into the YWS2 study and have a median follow of 6 years. They expect to launch the internet-based YWS2i study in the coming months.
This research will lead not only to new insights to inform future care and research but will directly enhance the care of young women with breast cancer and serve to accelerate accrual to other studies relevant to this vulnerable population.
Ann Partridge, MD, MPH is a medical oncologist and clinical researcher focused on improving the care and outcomes of patients with cancer, with a focus on treatment, survivorship, and psychosocial issues facing women with breast cancer. She founded and directs the Program for Young Women with Breast Cancer, and serves as the Director of the Adult Survivorship Program at Dana-Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital. She serves on several committees including as co-Chair of the Alliance for Clinical Trials Breast Committee and Chair for the Federal Advisory Committee to the Center for Disease Control (CDC) on Breast Cancer in Young Women. Dr. Partridge has published numerous manuscripts and lectures both nationally and internationally on issues of cancer survivorship and young women with breast cancer, in particular and has received grants and awards recognizing her work in this area. Dr. Partridge graduated from Georgetown University, earned her MD at Cornell University, trained in internal medicine at the Hospital of the University of Pennsylvania, and completed hematology and medical oncology fellowships at DFCI. She received a master’s degree in public health at the Harvard School of Public Health.
BCRF Investigator Since
The Pink Agenda Award